Device Trial Radar · NCT03364114
Endorotor Resection In Refractory Barrett's Dysplasia Patients
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
15
Actual
Start
Feb 9, 2018
Primary completion
Mar 24, 2026
Study completion Mar 24, 2026
Sponsor
- Lead sponsor
- Interscope, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 6, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 30 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the clinical trial is to evaluate the EndoRotor®'s ability to completely remove areas of Barrett's esophagus considered refractory after 3 failed ablation treatments (Radiofrequency Ablation (RFA) and/or Cryotherapy) or in patients with at least 1 failed ablative procedure (RFA and/or Cryotherapy) and are intolerant to the procedure due to pain, where intolerant is defined as post-dysphagia or odynophagia persisting for 24 hours or greater or requiring narcotic analgesia for a duration of more than 24 hours.
Conditions
- Barrett's Esophagus With Dysplasia
Interventions
EndoRotor Mucosal Resection SystemDevice
The EndoRotor® Endoscopic Mucosal Resection System is an automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract for benign neoplastic or pre-malignant tissue removal by interventional gastroenterologists and GI surgeons. The EndoRotor® System performs both tissue dissection and resection with a single device through an endoscope's instrument biopsy channel.
Continued AblationDevice
Continued ablation control shall include either cryotherapy or continued radial frequency ablation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of complete removal of refractory Barrett's esophagusTime frame: 12 months
- Rate of device- and procedure-related serious adverse events (SAEs)Time frame: 12 months
Locations
3 sites in 3 countries. Site status is shown where the registry gives one.
The Mayo Clinic
Rochester, Minnesota
Sahlgrenska University Hospital
Gothenburg, Sweden
NHS University College Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.